Prof. PeptideProf. Peptide
Guide

How is GHK-Cu dosed?

GHK-Cu is a three-amino-acid peptide bound to copper, sold as a cosmetic skin-care ingredient and, separately, as research-grade powder. No trial has set a dose and no GHK-Cu drug is FDA-approved. This page reports the doses its human studies used, the topical strengths and injection protocols clinics publish, and the side effects and FDA status that go with each route.

Topic: The doses GHK-Cu has been given in people, study by study, and the doses clinics publish, by route

Audience: Anyone comparing a GHK-Cu dose figure against what was studied and by which route

Reading time: 8–10 minutes

The human studies are on the skin; the injection doses are clinic practice

GHK-Cu on its own has been studied in people only on the skin. It was injected only into the scalp, as one of six active ingredients in a hair formulation. The injection doses on this page are what clinics publish, not trial results. Every figure on this page is a fact about a specific study or clinic, not a recommendation.

Has any trial set a GHK-Cu dose?

No trial has set a GHK-Cu dose. Its controlled human trials applied it to the skin: a nano-carrier serum twice daily for 8 weeks in 40 women, and skin-care products after laser resurfacing in a small trial. A registered wound trial applies a 0.1% w/w gel once daily for 14 days and has no results yet. The GHK-Cu profile covers its reported uses, how clinics explain its mechanism, its side effects and its legal status; this guide sets the study doses and clinic doses side by side.

GHK-Cu doses come in two units that do not convert into each other: topical products state a percentage strength (0.1% to 0.5% in the sources below), and injection protocols state micrograms. Research-grade vials are sold in milligrams, often 50 mg.

How do clinics dose GHK-Cu?

Clinics mostly prescribe GHK-Cu for the skin, as a compounded 0.5% cream, facial serum or scalp solution applied daily. Clinics that inject it commonly give it by subcutaneous injection once a day; the range reported runs from 200 mcg a day to 2,000 mcg (2 mg) a day, or 1,000 to 2,000 mcg (1–2 mg) two to three times a week. Courses run 4 to 6 weeks, 30-day cycles followed by a 30-day break, or 3 to 6 months of continuous use. These are clinic practice, not trial doses: no clinic ties its figure to a study.

Clinics describe results building gradually: 4 to 8 weeks for a 0.5% facial serum, a few weeks to two to three months for a scalp solution, about two months before judging a cream, and 3 to 6 months for visible skin and hair results from injections. Clinics also report that strong skin actives such as high-strength vitamin C, retinoids or acids can compete with or break down the peptide on the skin. Reconstitution arithmetic for a research vial is on the GHK-Cu reconstitution calculator, which converts a vial and water volume into syringe units and sets no schedule.

GHK-Cu doses as clinics publish them. The clinics listed are representative of those that publish a protocol. Clinic practice, not trial doses.
ClinicRouteDose as publishedSchedule and course
Perfect BSubcutaneous injection, before bed, at least 2 hours after the last meal1,000 mcg (1 mg) a day on days 1–15, then 2,000 mcg (2 mg) a day on days 16–30 (4 and 8 units of a 25 mg/mL vial)30 days on, then a 30-day break
Moonshot MedicalSubcutaneous injection, abdomen or thigh200–600 mcg a day, or 1,000–2,000 mcg (1–2 mg) two to three times a week3–6 months of consistent use
Defy MedicalSubcutaneous injectionCustomized strengths, set by the prescriberOnce daily for 4 to 6 weeks
PruCompounded (503A) cream on the skin0.5%, 30 g tubeAbout two months of consistent use before judging results
Defy MedicalFacial serum on the skin0.5%Applied daily; results often within 4–8 weeks, per the clinic
Defy MedicalScalp solution0.5%Applied daily; a few weeks to two to three months, per the clinic

The one registered trial

Topical GHK-Cu Gel for Acute Skin Wound Healing

NCT07437586

Recruiting; no results posted on ClinicalTrials.gov

Design: Phase 2, randomized trial testing whether a topical GHK-Cu gel speeds healing of small, standardized skin wounds in healthy adults, versus a matching vehicle gel. Each participant receives two 5-mm punch-biopsy wounds on the upper arm, one randomized to each gel.

Arms: 60 participants planned (estimated). GHK-Cu gel: 0.1% w/w, applied as a thin film (approximately 0.5 g) once daily for 14 days, versus a matching vehicle gel.

The only registered trial of GHK-Cu; it has posted no efficacy or safety results yet.

What doses have human studies of GHK-Cu used?

GHK-Cu’s human studies used topical products, with one exception: a scalp-injection study of a formulation with five other active ingredients. Two are published controlled trials, one of them in a journal not indexed in PubMed; two were never published as peer-reviewed papers; and the injection study had no control group. No human study of injected GHK-Cu on its own has been published.

Badenhorst et al. 2016: nano-lipid-carrier wrinkle serum (on the skin)

Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. J Aging Sci. 2016;4:166. DOI 10.4172/2329-8847.1000166.

Design: Randomized, double-blind trial in 40 women aged 40–65, comparing GHK-Cu encapsulated in a nano-lipid carrier, the carrier alone, and a commercial comparator serum (Matrixyl 3000), applied twice daily to facial skin for 8 weeks.

Outcome reported: Wrinkle volume 31.6% lower than with Matrixyl 3000 (p=0.004); wrinkle volume 55.8% lower (p<0.001) and wrinkle depth 32.8% lower (p=0.012) than with the carrier alone.

A published controlled trial, in a journal not indexed in PubMed/MEDLINE; the result belongs to that one formulation.

Miller et al. 2006: after CO2 laser resurfacing (on the skin)

Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. PMID 16847171.

Design: Patients were randomized after circumoral CO2 laser resurfacing to skin-care regimens with or without GHK-Cu; 13 completed the study, evaluated over 12 weeks.

Outcome reported: No significant difference between groups in resolution of redness or in wrinkle improvement; patients using GHK-Cu rated overall skin quality higher on a questionnaire (P = .04).

A small randomized trial; its abstract reports no adverse-event data.

Leyden et al. 2002: facial and eye cream (meeting proceedings, never published as papers)

Leyden J, et al. Proceedings of the American Academy of Dermatology 60th Annual Meeting, New Orleans, February 22–27, 2002, pp. 68–69. Known from Pickart & Margolina, Int J Mol Sci 2018.

Design: Two studies: a GHK-Cu facial cream in 71 women and a GHK-Cu eye cream in 41 women, each applied for 12 weeks.

Outcome reported: As the 2018 review summarizes them: the facial cream increased skin density and thickness, reduced laxity, improved clarity and reduced fine lines and wrinkle depth; the eye cream performed better than placebo and a vitamin K cream.

Meeting proceedings only, with no peer-reviewed paper or PMID: the weakest tier of the human evidence cited for GHK-Cu.

Kapoor et al. 2018: scalp injections of a mixed hair formulation

Kapoor R, et al. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth. J Cosmet Laser Ther. 2018;20(6):369-379. PMID 29482481.

Design: Open-label, single-arm pilot in 1,000 patients given intradermal scalp injections once every 3 weeks for eight sessions, of a formulation holding five growth factors and copper tripeptide-1 (GHK-Cu).

Outcome reported: Significant reduction in hair fall on the hair-pull test in 83% of patients; the authors reported that treatment was well tolerated.

No control group, and GHK-Cu was one of six active ingredients, so its own part cannot be separated.

What side effects have been reported?

GHK-Cu’s side effects in studies are recorded only for skin use and the mixed scalp formulation, and clinics list mostly local reactions. FDA states that there are limited data in humans on the safety of compounded injectable GHK-Cu.

  • Wrinkle trial: 39 of 40 women tolerated the serums over 8 weeks; one had minor skin reactions on both sides of the face, stopped, and recovered without medical treatment.
  • Scalp-injection study: the authors reported that treatment was well tolerated. The post-laser trial’s abstract reports no adverse-event data.
  • Clinics list mild skin irritation or a mild allergic reaction for topical use, and injection-site redness (the most common), tenderness, swelling or temporary discoloration at the site for injections; they list Wilson’s disease, active liver disease, pregnancy and nursing as contraindications.
  • FDA: compounded injectable GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities.”

The GHK-Cu profile’s side-effects section lists the full set of cautions and screening clinics publish.

Is GHK-Cu legal to compound?

FDA treats GHK-Cu differently by route. Non-injectable GHK-Cu is in 503A Category 1, under evaluation, which clinics describe as allowing it to be compounded while FDA finishes its review; the injectable route is on FDA’s safety-risk page. No GHK-Cu drug is FDA-approved.

FDA’s 503A nominations list (updated May 14, 2026) records that “GHK-Cu (except for injectable routes of administration)” was removed from category 1 on April 22, 2026, when its nominations were withdrawn; that on May 5, 2026 one nominator clarified it meant to withdraw only the injectable route; and that non-injectable GHK-Cu will be added back to category 1. FDA “intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list.”

FDA’s page of bulk substances that may present significant safety risks (content current as of April 22, 2026) lists “GHK-Cu (for injectable routes of administration)” among substances previously in category 2 whose nominations were withdrawn: “Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.”

GHK-Cu was not on the agenda of the committee’s July 23–24, 2026 meeting, and no FDA evaluation document for it has been published. FDA has issued no warning letter specifically naming GHK-Cu; two 2026 warning letters to peptide vendors Prof. Peptide tracks (Peptide Partners LLC, Royal Peptides LLC) were checked directly, and neither cites GHK-Cu among the substances named.

Clinics dispense compounded GHK-Cu by prescription from licensed compounding pharmacies. Topical GHK-Cu is also sold as a cosmetic skin-care ingredient. Research-grade GHK-Cu powder, of the kind sold by the vendors Prof. Peptide tracks, is not an approved product and is sold labeled for laboratory research use, not for human administration.

FAQ

Has injectable GHK-Cu been studied in humans?
Not on its own. The one human study that injected GHK-Cu gave scalp injections of a hair formulation that also held five growth factors, so GHK-Cu's part cannot be separated (Kapoor 2018, 1,000 patients, no control group). The other human studies applied it to the skin. FDA states that there are limited data in humans to inform the safety of compounded injectable GHK-Cu.
What dose do clinics commonly use for GHK-Cu?
Clinics mostly prescribe GHK-Cu for the skin, as a compounded 0.5% cream, serum or scalp solution applied daily. Clinics that inject it commonly give it by subcutaneous injection once a day; the range reported runs from 200 mcg a day to 2,000 mcg (2 mg) a day, or 1,000 to 2,000 mcg (1–2 mg) two to three times a week, over 4 to 6 weeks, 30-day cycles with a 30-day break, or 3 to 6 months. No clinic ties its figure to a trial.
What is the strongest human study of GHK-Cu?
The largest completed controlled trial is Badenhorst et al. 2016: a randomized, double-blind trial in 40 women aged 40 to 65 who applied a nano-carrier GHK-Cu serum to the face twice daily for 8 weeks; wrinkle volume fell 55.8% against the plain serum and 31.6% against a Matrixyl 3000 product. It is published in a journal not indexed in PubMed. The only registered trial, NCT07437586 (a 0.1% w/w wound gel, 60 planned), is still recruiting and has posted no results.
Is the wrinkle-reduction study behind GHK-Cu's cosmetic reputation a strong one?
It is a real randomized, double-blind trial, but small and narrow. Badenhorst et al. 2016 tested one nano-lipid-carrier serum in 40 women over 8 weeks: 55.8% lower wrinkle volume and 32.8% lower wrinkle depth than the carrier alone, and 31.6% lower wrinkle volume than a commercial Matrixyl 3000 serum. The Journal of Aging Science is not indexed in PubMed/MEDLINE. Two other often-cited studies, Leyden et al. 2002 (a facial cream in 71 women and an eye cream in 41, each over 12 weeks), are American Academy of Dermatology meeting proceedings known from a 2018 review, with no peer-reviewed paper to check.
What concentration is used in topical GHK-Cu?
The registered wound trial (NCT07437586) uses a 0.1% w/w gel, applied as a thin film of about 0.5 g once daily for 14 days. Clinics commonly prescribe a compounded 0.5% cream, facial serum or scalp solution, applied daily. A topical percentage is a strength of a formulation on the skin and does not translate into an injected amount in micrograms.
What side effects have been reported for GHK-Cu?
In the 8-week wrinkle trial, 39 of 40 women tolerated the serums; one had minor skin reactions on both sides of the face, stopped, and recovered without medical treatment. The scalp-injection study's authors reported that treatment was well tolerated. Clinics list mild skin irritation or a mild allergic reaction for topical use, and injection-site redness, tenderness or swelling for injections. FDA states that compounded injectable GHK-Cu may pose a risk of immunogenicity.
What is GHK-Cu's current FDA compounding status?
FDA splits it by route. Non-injectable GHK-Cu ("GHK-Cu (except for injectable routes of administration)") is back in 503A Category 1, under evaluation, after one nominator clarified on May 5, 2026 that it meant to withdraw only the injectable route. "GHK-Cu (for injectable routes of administration)" is on FDA's safety-risk page among substances previously in category 2 whose nominations were withdrawn. FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. No GHK-Cu drug is FDA-approved.

References

  1. ClinicalTrials.gov. Topical GHK-Cu Gel for Acute Skin Wound Healing, NCT07437586. Phase 2, recruiting, 60 planned; 0.1% w/w gel once daily for 14 days. Read November 6, 2026. https://clinicaltrials.gov/study/NCT07437586
  2. Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci. 2016;4:166. Twice-daily application, 40 women, 8 weeks; read November 6, 2026. https://www.walshmedicalmedia.com/open-access/effects-of-ghkcu-on-mmp-and-timp-expression-collagen-and-elastin-production-and-facial-wrinkle-parameters-2329-8847-1000166.pdf
  3. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. PMID 16847171. Abstract read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/16847171/
  4. Kapoor R, et al. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth. J Cosmet Laser Ther. 2018;20(6):369-379. PMID 29482481. Abstract read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/29482481/
  5. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. Review citing the Leyden et al. 2002 AAD meeting proceedings (its references 14 and 15), which have no PMID or paper of their own; read November 6, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  6. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1, 2 and 3). Updated May 14, 2026; read November 6, 2026. https://www.fda.gov/media/94155/download
  7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of April 22, 2026; read November 6, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  8. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, July 23–24, 2026: final agenda (GHK-Cu not listed). Read November 6, 2026. https://www.fda.gov/media/193771/download
  9. Perfect B Aesthetic Medicine, Doral, Florida. GHK-Cu Dosage and Protocol: The 30-Day Cycle; medically reviewed by Valeria Marulanda, FNP-BC. Cited for its own published protocol and timing; read November 6, 2026. https://www.perfectb.com/?p=21593
  10. Moonshot Medical and Performance, Park Ridge, Illinois. GHK-Cu Peptide: Benefits, Dosing & Anti-Aging Effects; medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC, published March 24, 2026. Cited for its own published dose, course, side effects and contraindications; read November 6, 2026. https://moonshotmp.com/learn/ghk-cu/
  11. Defy Medical. GHK Copper Peptides for Skin and Hair. Cited for its 0.5% facial serum and scalp solution, their stated timelines, and its injectable protocol (once daily for 4 to 6 weeks); read November 6, 2026. https://www.defymedical.com/blog/ghk-copper-peptide-for-skin-and-hair/
  12. Pru. Copper peptides (GHK-Cu); by the pru team, updated July 9, 2026. Cited for its compounded 0.5% cream, timing and skin-active notes, side effects and status account; read November 6, 2026. https://joinpru.com/blog/copper-peptides

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated